武清区龙济男子割包皮费用(武清和平龙济医院有效治疗) (今日更新中)

BEIJING, Sept. 1 (Xinhua) -- Chinese scientists have decided to reschedule the launch of the Tiangong-1, an unmanned space module, due to the failed launch of an experimental orbiter, a spokesperson with the project said Thursday.The decision to delay the launch was based on the consideration that the carrier rocket Long-March II-F, which would be used for the upcoming launch, belongs to the same series as the malfunctioning one that led to the experimental orbiter SJ-11-04 failing to enter Earth's orbit in August."As the investigation into the malfunction of the rocket Long-March II-C remains underway, it is not clear yet whether the malfunction is linked with the Long-March II-F," the unnamed spokesperson said.Previously, the Long-March II-F was expected to send the 8.5-metric ton Tiangong-1, or "Heavenly Palace 1," into space in the second half of this year to perform the nation's first space-docking procedure.The Tiangong-1 will dock with the unmanned Shenzhou-8 spacecraft, which will be sent into space after the Tiangong-1's launch."The specific launch date for the Tiangong-1 will be set based on the results of the investigation into the malfunctioning rocket," the spokesperson said, adding that the project's teams are currently double-checking every product that will be involved in the space-docking.The Shenzhou-8 spacecraft, the Long March II-F carrier rocket, and the Tiangong-1 have all been transferred to the Jiuquan Satellite Launch Center in northwest China's Gansu Province, the spokesperson said.

BEIJING, July 25 (Xinhuanet) -- More than one in three births in the U.S. are  delivered by C-section, which is an all time high and an increase of 25 percent over seven years, according to news reports Monday quoting a new study.Based on data from 19 states, C-section, or Cesarean, deliveries shot up from 27 percent of all births in 2002 to 34 percent in 2009, said the study by HealthGrades.  HealthGrades is an independent health care ratings organization with information on physicians, dentists and 5,000 hospitals in the nation.The study noted that the states with the highest rates are Texas, New Jersey and Florida while Utah, Colorado and Wisconsin are the lowest.Experts hold C-section deliveries are most suitable when vaginal delivery puts the health of the woman or child at risk, but also attributing the reason of increase to convenience, less risk, fertility and general attitudes.However, Divya Cantor, MD, MBA and HealthGrades Senior Physician Consultant. cautioned, "C-sections are rising, and there needs to be a little bit more scrutiny from the person who is having the C-section as well as doctors and hospitals."

SINGAPORE, July 6 (Xinhua) -- A team of researchers in Singapore has designed a tube with special robotic hands that allows doctors to perform surgery on a patient's inner organs without resulting in scars, local media reported on Wednesday.The special "robotic hands" were fixed to the tube to access a patient's stomach. Compared with traditional methods which use only one robotic hand, the new device known as master and slave transluminal endoscopic robot, or MASTER, is more nimble, thereby allowing complex operations, the Lianhe Zaobao reported.Louis Phee, an associate professor at the Nanyang Technological University who led the team of researchers, had spent six years to develop the gadget, which cut an eight-hour procedure to just 17 minutes, said doctors at India's Asian Institute of Gastroenterology.The gadget, still in the trial stage, has been tested earlier this month on three patients at the Indian hospital. It is also expected to be tried out in Germany and China's Hong Kong later. The patients can leave the hospital much sooner than they would have using traditional gadgets.Phee said he expected the gadget to be available on the market as early as three years from now, after going through clinical trials and getting the approval from authorities.He also saw a potential for the gadget to be used on other organs by cutting a small spit on stomach that allows the gadget to go through to access the site.

SAN FRANCISCO, June 28 (Xinhua) -- Microsoft on Tuesday launched its cloud service Office 365, which was the software giant's answer to competing products from Google and other companies.The service includes on-line versions of Word, PowerPoint, Excel, Outlook and other Office applications, as well as Microsoft 's communication and collaboration tools such as Exchange, SharePoint and Lync.It will allow users to work on files and documents at the same time using instant messaging and video-conferencing."Where does Office meet the cloud? It's Office 365, the absolute best productivity and collaboration service for business around the world," Microsoft CEO Steve Ballmer said at a webcast event.Microsoft said that Office 365 is now available in 40 markets with choices for small and big businesses ranging from 2 to 27 U.S. dollars per user per month.Office 365 will compete directly with the web-based Google Apps, which Google sells for 50 dollars per user per year.Microsoft's service was introduced in beta last year and the company said response was enthusiastic with more than 200,000 organizations signed up and began testing it in a few months."With a few clicks, Office 365 levels the playing field, giving small and midsize businesses powerful collaboration tools that have given big businesses an edge for years," Ballmer said in a statement.

LOS ANGELES, June 5 (Xinhua) -- A latest study has found no evidence that screening for ovarian cancer may reduce the risk of dying from the disease, it was reported on Sunday.Screening, however, does increase the likelihood of unnecessary invasive procedures, according to researchers at the University of Utah.The researchers presented their findings at an on-going meeting of the American Society of Clinical Oncology in Chicago, The Los Angeles Times said.Researchers studied 78,216 women, ages 55 to 74, who participated in the National Cancer Institute's Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. Half of the women received the usual care from their OB-gyns, and half received a CA 125 screening every year for six years and an ultrasound every year for four years. They were then followed for a maximum of 12 years.The researchers observed 212 ovarian cancers in the screened group and 176 in the normal care group. There were 118 ovarian cancer deaths in the screened group and 100 in the normal care group. The differences were not statistically significant. Overall, there were 2,924 deaths from all causes in the screened group and 2,914 in the normal care group.But the researchers also observed that 3,285 women had false- positive diagnoses from the screening. Among those, 1,080 underwent surgery that included an oophorectomy (surgical removal of one or both ovaries). Fifteen percent of those who had surgery developed major complications as a result. Overall, 1,771 women in the screened group (7.7 percent) had an oophorectomy, compared with 1,304 in the normal care group (5.8 percent)."We conclude that annual screening for ovarian cancer ... does not reduce disease-specific mortality in women at average risk for ovarian cancer but does increase invasive medical procedures and associated harms," the researchers said in the study.New data presented at the meeting also showed that the widely used cancer drug Avastin can improve treatment of ovarian cancer, The Times said.About 21,880 American women are diagnosed with ovarian cancer each year and about 13,850 die from it, according to the American Cancer Society. Because it produces few symptoms, the disease is typically not diagnosed until it has become advanced and spread throughout the body. As a result, five-year survival is only about 30 percent, and the disease is one of the five most deadly cancers among women. Being able to detect the cancer at an earlier stage when it might be more curable could thus, theoretically, improve the survival rate.The tests most commonly used to detect ovarian cancer include a transvaginal ultrasound to look for tumor masses and a blood test that screens for increased levels of a tumor marker called CA 125.

来源：资阳报